BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nathoo N, Mackie A. Treating depression in multiple sclerosis with antidepressants: A brief review of clinical trials and exploration of clinical symptoms to guide treatment decisions. Mult Scler Relat Disord 2017;18:177-80. [PMID: 29141805 DOI: 10.1016/j.msard.2017.10.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Peres DS, Theisen MC, Fialho MFP, Dalenogare DP, Rodrigues P, Kudsi SQ, Bernardes LB, Ruviaro da Silva NA, Lückemeyer DD, Sampaio TB, Pereira GC, Mello FK, Ferreira J, Bochi GV, Oliveira SM, de David Antoniazzi CT, Trevisan G. TRPA1 involvement in depression- and anxiety-like behaviors in a progressive multiple sclerosis model in mice. Brain Res Bull 2021;175:1-15. [PMID: 34280479 DOI: 10.1016/j.brainresbull.2021.07.011] [Reference Citation Analysis]
2 Cohan SL, Hendin BA, Reder AT, Smoot K, Avila R, Mendoza JP, Weinstock-Guttman B. Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex). CNS Drugs 2021;35:743-67. [PMID: 34228301 DOI: 10.1007/s40263-021-00822-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Navaderi M, Rajaei S, Rahimirad S, Jafari Harandi A, Ghaleh Z, Falahati K, Behgar Z, Sedigh AM, Sanati MH. Identification of Multiple Sclerosis key genetic factors through multi-staged data mining. Multiple Sclerosis and Related Disorders 2020;39:101446. [DOI: 10.1016/j.msard.2019.101446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Ploughman M, Wallack EM, Chatterjee T, Kirkland MC, Curtis ME. Under-treated depression negatively impacts lifestyle behaviors, participation and health-related quality of life among older people with multiple sclerosis. Multiple Sclerosis and Related Disorders 2020;40:101919. [DOI: 10.1016/j.msard.2019.101919] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
5 Mihai DP, Nitulescu GM, Ion GND, Ciotu CI, Chirita C, Negres S. Computational Drug Repurposing Algorithm Targeting TRPA1 Calcium Channel as a Potential Therapeutic Solution for Multiple Sclerosis. Pharmaceutics 2019;11:E446. [PMID: 31480671 DOI: 10.3390/pharmaceutics11090446] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
6 Persson R, Lee S, Yood MU, Wagner MR, Minton N, Niemcryk S, Lindholm A, Evans AM, Jick S. Incident depression in patients diagnosed with multiple sclerosis: a multi-database study. Eur J Neurol 2020;27:1556-60. [PMID: 32397001 DOI: 10.1111/ene.14314] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Vorobeychik G, Black D, Cooper P, Cox A. Multiple sclerosis and related challenges to young women's health: Canadian expert review. Neurodegener Dis Manag 2020;10:1-13. [PMID: 32372725 DOI: 10.2217/nmt-2020-0010] [Reference Citation Analysis]
8 Taylor KL, Simpson S Jr, Jelinek GA, Neate SL, De Livera AM, Brown CR, O'Kearney E, Marck CH, Weiland TJ. Longitudinal Associations of Modifiable Lifestyle Factors With Positive Depression-Screen Over 2.5-Years in an International Cohort of People Living With Multiple Sclerosis. Front Psychiatry 2018;9:526. [PMID: 30425659 DOI: 10.3389/fpsyt.2018.00526] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
9 Mihai DP, Ungurianu A, Ciotu CI, Fischer MJM, Olaru OT, Nitulescu GM, Andrei C, Zbarcea CE, Zanfirescu A, Seremet OC, Chirita C, Negres S. Effects of Venlafaxine, Risperidone and Febuxostat on Cuprizone-Induced Demyelination, Behavioral Deficits and Oxidative Stress. Int J Mol Sci 2021;22:7183. [PMID: 34281235 DOI: 10.3390/ijms22137183] [Reference Citation Analysis]
10 Stamoula E, Siafis S, Dardalas I, Ainatzoglou A, Matsas A, Athanasiadis T, Sardeli C, Stamoulas K, Papazisis G. Antidepressants on Multiple Sclerosis: A Review of In Vitro and In Vivo Models. Front Immunol 2021;12:677879. [PMID: 34093579 DOI: 10.3389/fimmu.2021.677879] [Reference Citation Analysis]
11 Malygin VL, Boyko AN, Konovalova OE, Pahtusova EE, Dumbrova EV, Tishina IA, Malygin YV. [Anxiety and depressive psychopathological characteristics of patients with multiple sclerosis at different stages of disease]. Zh Nevrol Psikhiatr Im S S Korsakova 2019;119:58-63. [PMID: 31156243 DOI: 10.17116/jnevro20191192258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
12 Jones CD, Motl R, Sandroff BM. Depression in multiple sclerosis: Is one approach for its management enough? Mult Scler Relat Disord 2021;51:102904. [PMID: 33780807 DOI: 10.1016/j.msard.2021.102904] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Patten SB. Current perspectives on co-morbid depression and multiple sclerosis. Expert Review of Neurotherapeutics 2020;20:867-74. [DOI: 10.1080/14737175.2020.1806062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Drulovic J, Kisic-tepavcevic D, Pekmezovic T. Epidemiology, diagnosis and management of sexual dysfunction in multiple sclerosis. Acta Neurol Belg 2020;120:791-7. [DOI: 10.1007/s13760-020-01323-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
15 Carta MG, Paribello P, Anastasia A, De Berardis D, Nardi AE, Fornaro M. Pharmacological management of depression in patients with multiple sclerosis. Expert Opin Pharmacother 2018;19:1533-40. [PMID: 30207800 DOI: 10.1080/14656566.2018.1516207] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
16 Abdulla FA, Albagmi FM, Al-Khamis FA. Factors that influence quality of life in patients with multiple sclerosis in Saudi Arabia. Disabil Rehabil 2021;:1-9. [PMID: 33966564 DOI: 10.1080/09638288.2021.1919929] [Reference Citation Analysis]